Literature DB >> 14668654

Levetiracetam in the treatment of neuropathic pain: three case studies.

Michael J Price1.   

Abstract

CASE REPORTS: A 55-year-old woman presented with numbness and pain in both lower extremities. The pain was of sudden onset and of 4 months' duration. A nerve conduction study demonstrated a bilateral sensorimotor peripheral neuropathy with axonal and demyelinating features of a mild degree. Initial treatment with oral thiamine and topiramate had little efficacy and caused unacceptable side effects. A switch to 1500 mg bid levetiracetam plus nortriptyline resulted in a 60% improvement in pain symptoms. A 75-year-old man presented with numbness in both feet of 5 years' duration. The sensation of numbness had progressed to persistent pain, resulting in sleep disruption. The patient's use of oral thiamine did not lead to pain relief, but the addition of 500 mg levetiracetam once in the evening led to a complete resolution of his pain and to sleep improvement. A 67-year-old obese male was referred from a podiatrist with progressive dysfunction in both lower extremities that developed over a 1-year period. Walking more than a few steps resulted in sharp, shooting pain that at night disrupted sleep. A nerve conduction study demonstrated a severe bilateral sensorimotor peripheral neuropathy with axonal and demyelinating features. Treatment with 1000 mg levetiracetam bid resulted in complete absence of pain.
CONCLUSIONS: In these 3 case studies, levetiracetam was demonstrated to be an effective therapy in the treatment of neuropathic pain. It has the benefits of a low incidence of adverse events and an improvement in patients' sleep.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14668654     DOI: 10.1097/00002508-200401000-00007

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  9 in total

Review 1.  A systematic review of pharmacologic treatments of pain after spinal cord injury.

Authors:  Robert W Teasell; Swati Mehta; Jo-Anne L Aubut; Brianne Foulon; Dalton L Wolfe; Jane T C Hsieh; Andrea F Townson; Christine Short
Journal:  Arch Phys Med Rehabil       Date:  2010-05       Impact factor: 3.966

Review 2.  Benefit-risk assessment of levetiracetam in the treatment of partial seizures.

Authors:  Bassel Abou-Khalil
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  SV2 regulates neurotransmitter release via multiple mechanisms.

Authors:  Amy Nowack; Jia Yao; Kenneth L Custer; Sandra M Bajjalieh
Journal:  Am J Physiol Cell Physiol       Date:  2010-08-11       Impact factor: 4.249

Review 4.  Painful and involuntary multiple sclerosis.

Authors:  Francesca Bagnato; Diego Centonze; Simonetta Galgani; Maria Grazia Grasso; Shalom Haggiag; Stefano Strano
Journal:  Expert Opin Pharmacother       Date:  2011-02-17       Impact factor: 3.889

5.  Cotrafficking of SV2 and synaptotagmin at the synapse.

Authors:  Jia Yao; Amy Nowack; Patricia Kensel-Hammes; Richard G Gardner; Sandra M Bajjalieh
Journal:  J Neurosci       Date:  2010-04-21       Impact factor: 6.167

6.  Add-on Effect of Levetiracetam on Cognitive Activity of Carbamazepine and Topiramate Treated Healthy Rats.

Authors:  Priti Dhande; Satish Gonarkar; Dhara Sanghavi; Vijaya Pandit
Journal:  J Clin Diagn Res       Date:  2015-06-01

7.  Levetiracetam reverses synaptic deficits produced by overexpression of SV2A.

Authors:  Amy Nowack; Erik B Malarkey; Jia Yao; Adam Bleckert; Jessica Hill; Sandra M Bajjalieh
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

8.  Current aproach to cancer pain management: Availability and implications of different treatment options.

Authors:  Hrachya Nersesyan; Konstantin V Slavin
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

Review 9.  Current Status of the New Antiepileptic Drugs in Chronic Pain.

Authors:  Harpreet S Sidhu; Akshay Sadhotra
Journal:  Front Pharmacol       Date:  2016-08-25       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.